Euroopa Liit - eesti - EMA (European Medicines Agency)

zaklady farmafarmaceutyczne polpharma s.aceutyczne polpharma s.a. - dimetüülfumaraat - sclerosis multiplex, relapsing-remitting - immunosupressandid - dimethyl fumarate polpharma is indicated for the treatment of adult patients with relapsing remitting multiple sclerosis.

Euroopa Liit - eesti - EMA (European Medicines Agency)

teva gmbh - dimetüülfumaraat - multiple sclerosis, relapsing-remitting; multiple sclerosis - immunosupressandid - dimethyl fumarate teva is indicated for the treatment of adult and paediatric patients aged 13 years and older with relapsing remitting multiple sclerosis (rrms).

Euroopa Liit - eesti - EMA (European Medicines Agency)

accord healthcare s.l.u. - dimetüülfumaraat - multiple sclerosis, relapsing-remitting; multiple sclerosis - immunosupressandid - dimethyl fumarate accord is indicated for the treatment of adult and paediatric patients aged 13 years and older with relapsing remitting multiple sclerosis (rrms).

Euroopa Liit - eesti - EMA (European Medicines Agency)

mylan ireland limited - dimetüülfumaraat - sclerosis multiplex, relapsing-remitting - immunosupressandid - dimethyl fumarate mylan is indicated for the treatment of adult patients with relapsing remitting multiple sclerosis.

Euroopa Liit - eesti - EMA (European Medicines Agency)

laboratorios lesvi s.l. - dimetüülfumaraat - sclerosis multiplex, relapsing-remitting - immunosupressandid - dimethyl fumarate neuraxpharma is indicated for the treatment of adult patients with relapsing remitting multiple sclerosis.

Euroopa Liit - eesti - EMA (European Medicines Agency)

biogen netherlands b.v. - diroximel fumarate (biib098) - sclerosis multiplex, relapsing-remitting - immunosupressandid - vumerity is indicated for the treatment of adult patients with relapsing remitting multiple sclerosis (see section 5. 1 for important information on the populations for which efficacy has been established).

Euroopa Liit - eesti - EMA (European Medicines Agency)

astrazeneca ab - glycopyrronium, formoterol fumarate dihydrate - kopsuhaigus, krooniline obstruktiivne - formoterol ja glycopyrronium bromiid - bevespi aerosphere on näidustatud hooldus bronchodilator ravi, et leevendada sümptomeid täiskasvanud patsientidel, kellel on krooniline obstruktiivne kopsuhaigus (copd).

Euroopa Liit - eesti - EMA (European Medicines Agency)

astrazeneca ab - formoterol fumarate dihydrate, glycopyrronium bromide, budesonide - kopsuhaigus, krooniline obstruktiivne - ravimid hingamisteede obstruktiivsete haiguste, - trixeo aerosphere is indicated as a maintenance treatment in adult patients with moderate to severe chronic obstructive pulmonary disease (copd) who are not adequately treated by a combination of an inhaled corticosteroid and a long acting beta2 agonist or combination of a long-acting beta2 agonist and a long acting muscarinic antagonist.

Euroopa Liit - eesti - EMA (European Medicines Agency)

covis pharma europe b.v. - formoterol fumarate dihydrate, aclidinium bromide - kopsuhaigus, krooniline obstruktiivne - ravimid hingamisteede obstruktiivsete haiguste, - brimica genuair on näidustatud kroonilise obstruktiivse kopsuhaiguse (kok) raviks täiskasvanud patsientidel, kes hoiavad bronhodilataatorit õhuvoolu takistamiseks ja sümptomite leevendamiseks..

Eesti - eesti - Ravimiamet

teva gmbh - dimetüülfumaraat - gastroresistentne kõvakapsel - 120mg 100tk; 120mg 14tk